The acquisition is expected to expand OPKO’s business in Chile and Mexico in addition to obtaining permission for commercialization of OPKO 4KScore prostate cancer test in Brazil.
OPKO chairman and chief executive officer Phillip Frost said, "We are excited to establish our initial footprint in the most important growth market in South America and initiate commercial efforts towards the introduction of our 4Kscore™ test in the Brazilian market."
OPKO 4KScore prostate cancer test will be commercialized as a reference laboratory test in Brazil.
The company also obtains local marketing approval for care microfluidics disposable test cassettes.